Contributions
Abstract: PB1881
Type: Publication Only
Background
Follicular lymphomas are usually defined as incurable diseases with a natural history characterized by continuous relapses.
Aims
This study was launched to evaluate after a long observation period the causes of death during follow-up.
Methods
All patients with histologically confirmed diagnosis of follicular lymphomas grade I-II or IIIa were selected from our data base starting from January 2000 untill December 2004 in such a way to have more than 10 years of observation for alive patients. We considered all patients with this diagnosis regardless to treatment and considering also patients followed with watch and wait. Patients were followed with ambulatory evaluation and for those lost to follow-up consulting the regional cancer registry.
Results
One hundred and fourthy-six patients were diagnosed and treated at our Institution. The median age at diagnosis was 61 years (range 30-87). Stage I-II in 47 patients, III-IV in 86. Bone marrow biopsy was positive in 87 patients, FLIPI 0-1 in 40, FLIPI 2 in 48, FLIPI 3 in 40 and FLIPI 4 in 18 patients. According to treatment 98 patients were treated with antracycline containing regimens, 34 with fludarabine containing regimens and 14 were observed or treated with radiotherapy. Rituximab was used in 98 patients, as sequential treatment in 74 or chemotherapy combined in 24; 48 patients did not use rituximab. The median observation period for alive patients was 13,4 years (range 11-15 years) and 8 years (range 0,09-15 years) for dead patients. Sixty-five patients dead during this long period of observation and the causes were: 35 due to lymphoma progression (54%), 16 second neoplasms (25%), 12 other disease (18%), 1 car accident and 1 unknown. The overall survival with a median period of observation of 127 months (range 2-196) was 71%. In univariate analysis the best overall survival was statistically associated with low FLIPI score, the use of Rituximab and the obtainment of complete remission. In multivariate analysis FLIPI 0-1 and the obtainment of complete remission manteined the significance. Exactly the same results were observed if we considered the cause specific mortality.
Conclusion
Session topic: 19. Indolent Non-Hodgkin lymphoma - Clinical
Keyword(s): Survival, Follicular lymphoma, Causes of death
Abstract: PB1881
Type: Publication Only
Background
Follicular lymphomas are usually defined as incurable diseases with a natural history characterized by continuous relapses.
Aims
This study was launched to evaluate after a long observation period the causes of death during follow-up.
Methods
All patients with histologically confirmed diagnosis of follicular lymphomas grade I-II or IIIa were selected from our data base starting from January 2000 untill December 2004 in such a way to have more than 10 years of observation for alive patients. We considered all patients with this diagnosis regardless to treatment and considering also patients followed with watch and wait. Patients were followed with ambulatory evaluation and for those lost to follow-up consulting the regional cancer registry.
Results
One hundred and fourthy-six patients were diagnosed and treated at our Institution. The median age at diagnosis was 61 years (range 30-87). Stage I-II in 47 patients, III-IV in 86. Bone marrow biopsy was positive in 87 patients, FLIPI 0-1 in 40, FLIPI 2 in 48, FLIPI 3 in 40 and FLIPI 4 in 18 patients. According to treatment 98 patients were treated with antracycline containing regimens, 34 with fludarabine containing regimens and 14 were observed or treated with radiotherapy. Rituximab was used in 98 patients, as sequential treatment in 74 or chemotherapy combined in 24; 48 patients did not use rituximab. The median observation period for alive patients was 13,4 years (range 11-15 years) and 8 years (range 0,09-15 years) for dead patients. Sixty-five patients dead during this long period of observation and the causes were: 35 due to lymphoma progression (54%), 16 second neoplasms (25%), 12 other disease (18%), 1 car accident and 1 unknown. The overall survival with a median period of observation of 127 months (range 2-196) was 71%. In univariate analysis the best overall survival was statistically associated with low FLIPI score, the use of Rituximab and the obtainment of complete remission. In multivariate analysis FLIPI 0-1 and the obtainment of complete remission manteined the significance. Exactly the same results were observed if we considered the cause specific mortality.
Conclusion
Session topic: 19. Indolent Non-Hodgkin lymphoma - Clinical
Keyword(s): Survival, Follicular lymphoma, Causes of death